BARD1 Life Sciences Ltd (ASX: BD1) shares are galloping into the green today. This follows the company announcing it is presenting EXO-NET data at the International Society for Extracellular Vesicles conference.
At the time of writing, the BARD1 share price is trading at $2.62, up 6.5%.
Image source: Getty Images
EXO-NET data rallies shares
Investors are buying up BARD1 shares today on the back of the company's presentation of EXO-NET data.
Yesterday, the company announced it will launch its EXO-NET product at the virtual International Society of Extracellular Vesicles (ISEV) annual meeting. The product is the first to be produced on the company's molecular NET technology.
The conference is a hub for showcasing the best in extracellular vesicle science. BARD1 is presenting the results of its EXO-NET product at the conference. According to the company, EXO-NET is shown to be a novel approach for the rapid, pure, and high-yield capture of exosomes from complex samples. Such samples include body fluids such as plasma, urine, and saliva.
According to the release, BARD1 researchers showed that EXO-NET provides superior exosome-specific nucleic acid and protein yield and purity compared to market-leading products and methods.
An important trait, the new product can capture exosomes in 15 minutes.
Management commentary
Commenting on the opportunity for BARD1's latest product, chief scientific officer Dr Peter French said:
Being able to showcase the superior performance, flexibility and ease of use of EXO-NET on the global stage at ISEV2021 provides the Company with a great opportunity to embed EXO-NET into a range of research projects that are isolating and characterising exosomes for potential diagnostic and therapeutic applications.
Adding to these comments, CEO Dr Leearne Hinch stated:
It is exciting to release the results of our exosome research demonstrating that our next-generation EXO-NET product out-performed competitor products capturing exosomes rapidly, with high purity and yield from complex biofluids. EXO-NET has the potential to become the exosome isolation product of choice for researchers globally.
Unsurprisingly, the optimistic commentary surrounding the product has the BARD1 share price picking up in today's trade.
BARD1 share price recap
Despite a 36% fall from its 52-week high, the BARD1 share price has delivered superior returns over the last 12 months. While the S&P/ASX 200 Index (ASX: XJO) has gained around 25% in the past year, BARD1 shares have skyrocketed by more than 235%.
Accounting for today's move in the BARD1 share price, the company's market capitalisation now stands at $197 million.
